Navigation Links
AMDL, Inc. Reports 2008 Year End Financial Results and Fiscal Year 2009 Financial Targets
Date:4/15/2009

TUSTIN, Calif., April 15 /PRNewswire-FirstCall/ -- AMDL, Inc., (NYSE Alternext US: ADL), an international pharmaceutical company with operations in China and the US, today announced financial results for the fourth quarter and year ended December 31, 2008.

For the 12 months ended December 31, 2008, the Company demonstrated strong top-line growth and sales performance. Gross revenues increased over 124%, reaching just over $33.6 million compared to approximately $15 million for the same period in FY2007. The significant growth in revenues was due to an increase in sales of existing products in the growing China healthcare market, which included AMDL's best-selling human placenta extract (HPE)-based skin care product, Domperidone anti-emetic drug, and other high-quality ethical pharmaceutical products.

Gross profits for FY2008 increased to approximately $14.8 million compared to approximately $8.1 million for the same period in FY2007, with a gross profit margin of 52% of net sales as compared to a gross profit of 54% for the same period in FY2007. Gross profits increased approximately US$6.7 million from FY2007 to FY2008, primarily due to continued product sales growth in China. As a percentage of net revenues, gross profits declined slightly due to a change in AMDL's product mix, which shifted away from certain products reliant on a non-operating small injectable manufacturing line, to other slightly less profitable products. The Company also had an increase in the cost of raw materials and manufacturing overhead. The non-operating small injectable production line is back in trial production and AMDL expects to resume full production beginning in the second quarter FY2009. Operating income for the year ended December 31, 2008 totaled approximately US$3.3 million compared to a loss of approximately $1.79 million reported for the same period in 2007, an increase of
'/>"/>

SOURCE AMDL, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. AMDL, Inc. to Present at 5th Annual Winter Technology Conference Hosted by Security Research Associates, Inc.
2. AMDL, Inc. Issues Correction to January 30, 2009 Press Release Announcing Closing of Private Placement of Senior Notes
3. AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes
4. AMDL, Inc. Chairman & CEO Announces Expert Opinion on Chinas Economic Forecast
5. AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan
6. Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report
7. AMDL, Inc. Selected as #1 Small-Cap Stock Pick for 2009
8. Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Early Stage Breast Cancer Tumors
9. Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009
10. Study reports success in treating a rare retinal disorder
11. Johnson & Johnson Reports 2009 First-Quarter Results:
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:183 New Medicines in Development for Diabetes 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Ikaria 28R 29 Names New Chairman 14523 1Ikaria 28R 29 Names New Chairman 14523 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 1Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 4Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 6Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 7Jennerex Inc Receives EMEA Orphan Drug Designation for JX 594 for the Treatment of Hepatocellular Carcinoma 5557 1Jennerex Inc Receives EMEA Orphan Drug Designation for JX 594 for the Treatment of Hepatocellular Carcinoma 5557 2Jennerex Inc Receives EMEA Orphan Drug Designation for JX 594 for the Treatment of Hepatocellular Carcinoma 5557 3